Rachel Riechelmann: So happy to share my first Nature Disease Primers publication on Gastric neuroendocrine cancer
Rachel Riechelmann shared on X/Twitter:
“So happy to share my first Nature Reviews Disease Primers publication, together with brilliant colleagues Garcia-Carbonero’s Lab, Giuseppe Lamberti, Panzuto, Pavel, O’Toole, Ambrosini, Falconi, Rindi and Campana on Gastric neuro endocrinecancer.”
Source: Rachel Riechelmann/X
Dr. Rachel Riechelmann is the Director of the Clinical Oncology Department and Professor at AC Camargo Cancer Center, Sao Paulo, Brazil and also serves as the President of the Brazilian GI Tumors Group (GTG). She has more than 125 publications in peer-reviewed journals and is editor of the book Methods and Biostatistics in Oncology: Understanding Clinical Research as an Applied Tool, Springer 2018. Prof. Riechelmann is a member of ESMO Scientific Committees (Colorectal and NET), Latin American Society of GI Oncology (SLAGO), the European Society of Neuroendocrine Tumors Advisory Board and Chair – GI LACOG (Latin American Cooperative Oncology Group).
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023